Waltham, Massachusetts-based Thermo Fisher Scientific Inc. (TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. Valued at $220.3 billion by market cap, the company provides a portfolio of reagents, instruments, and consumables for research, drug development, and disease diagnosis, along with laboratory products and biopharma services. Shares of this leading provider of scientific research services and products have underperf ...

Diamond Hill Capital, an investment management company, released its “Large Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets continued their YTD rally in the third quarter of 2025, with the Russell 3000 Index gaining 8%, bringing the calendar-year returns to over 14%. The portfolio declined and underperformed the Russell 1000 Value Index in the quarter.  In addition, you can check the top 5 holdings of the fund to know its best picks in 2025. In its third-q ...

Core Insights - Polen Capital's "Polen Focus Growth Strategy" reported a gross return of 3.34% and a net return of 3.14% for Q3 2025, underperforming the Russell 1000 Growth Index at 10.51% and the S&P 500 Index at 8.12% [1] - The equity market's strong performance was attributed to enthusiasm for generative AI and strength in the semiconductor sector, alongside positive economic surprises and better-than-expected corporate earnings [1] Company-Specific Insights - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as a key stock, with a one-month return of 9.12% but a 52-week loss of 12.65%, closing at $524.58 per share with a market capitalization of $198.088 billion on October 13, 2025 [2] - Polen Focus Growth Strategy eliminated its position in Thermo Fisher Scientific to fund the purchase of Uber, citing ongoing macro, policy, and funding headwinds that are expected to persist [3] - Thermo Fisher Scientific's revenue grew 3% to $10.85 billion in Q2, and it ranked 26th among the 30 most popular stocks among hedge funds, with 117 hedge fund portfolios holding its stock at the end of Q2 [4]

Core Insights - Douglas Lane & Associates has increased its investment in Thermo Fisher Scientific by purchasing 16,745 shares valued at approximately $7.79 million, bringing its total holdings to 216,276 shares [2][11] - Following this purchase, Thermo Fisher Scientific accounts for 1.5% of the fund's reportable assets under management as of September 30, 2025 [3] Company Overview - Thermo Fisher Scientific reported a total revenue of $43.21 billion and a net income of $6.58 billion for the trailing twelve months [4] - The company has a dividend yield of 0.32% and its stock price was $534.68 as of October 9, 2025, reflecting a 12% decline over the past year [3][4] Business Performance - Thermo Fisher achieved a 3% revenue growth to $10.9 billion in its fiscal second quarter, with a 6% year-over-year increase in diluted earnings per share (EPS) to $4.28 [13] - The company has raised its fiscal guidance for 2025 to approximately $44 billion in sales, up from $42.9 billion the previous year [14] Investment Rationale - The current price-to-earnings (P/E) ratio of Thermo Fisher is lower than it was a year ago, suggesting that the stock is more attractively valued now [12] - The combination of rising revenue, increasing EPS, and a reasonable P/E ratio positions Thermo Fisher stock as a compelling buy opportunity [14]

Group 1 - Thermo Fisher Scientific Inc. (NYSE:TMO) has faced challenges due to COVID-19, with comparisons made to Danaher, which is perceived to have a stronger position currently [1][2] - Jim Cramer highlighted that while Thermo Fisher is a great company led by Marc Casper, he recommends Danaher for investment, indicating a preference for DHR over TMO [1][2] - Cramer advised against purchasing Thermo Fisher stock until there is an improvement in Chinese orders, citing the stock's recent struggles and its connection to the bearish outlook on China [2] Group 2 - The company provides a range of services including life sciences solutions, analytical instruments, diagnostics, lab products, and biopharma services [2] - There is a belief that certain AI stocks may offer better investment opportunities with higher upside potential and lower downside risk compared to Thermo Fisher [2]

Market Overview - The stock market experienced significant volatility in Q2 2025, with the S&P 500 reaching an all-time high by the end of June [1] - The market saw a drop of 7% from April 2 to April 7 due to the liberation day tariff announcement, followed by a rebound of over 22% from the April 7 low through the end of June [1] - The Russell 1000 Growth returned 17.8% and the S&P 500 returned 10.9% in the quarter, with large caps significantly outperforming small caps and growth outperforming value [1] Renaissance Large Cap Growth Strategy Performance - The strategy outperformed the S&P 500 Index but underperformed the Russell 1000 Growth benchmark [1] Company Focus: Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as an underperformer, with a one-month return of -0.11% and a 52-week loss of 21.70% [2] - As of September 09, 2025, Thermo Fisher's stock closed at $487.65 per share, with a market capitalization of $182.859 billion [2] - The company reported solid operating results but saw a decline of 18.5% in its stock price, attributed to lowered full-year guidance due to tariff-related macro weakness and uncertainty regarding NIH funding delays impacting academic and government customers [3]